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ABSTRACT 
 
 
 This project describes the technology of inserting foreign DNA into the genomes of 
animals to create transgenic animals that benefit society.  Transgenic animals have served as 
models for screening vaccines, producing drugs, or producing organs for patients awaiting 
transplants.  The first chapter describes transgenic technology, while chapter-2 shows examples 
of how these animals are used.  The third chapter introduces some of the ethical issues associated 
with this technology, while the fourth chapter describes the laws regulating the technology, and 
the pros and cons of animal patenting.  The authors finally provide their own unique perspectives 
on the issues addressed in the chapters. 
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PROJECT OBJECTIVES 
 
 
 The main objective of this project is to investigate the benefits and consequences of 
transgenic animal technology on society.  This technology that allows foreign genes to be 
inserted in animal’s genomes, is one of the most controversial bio-related technology today.  
Should animals be killed for the sake of saving human lives?  This project gives enough 
information for the reader to build their perspective on whether to support transgenic research. 
The first chapter informs the reader about the scientific methods used in transgenesis.  The 
second chapter focuses on its applications for different species. The third chapter addresses some 
of the ethical issues related to creating these animals on animal welfare and the environment, 
while the fourth chapter describes the history of legal issues related to patenting animals in 
different parts of the world. 
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Chapter-1: Transgenic Animal Technology 
Jeffrey Blanco 
 
Transgenic animals are genetically modified organisms containing foreign genes in their 
genome transplanted from another species. Transgenic animals are created by a process called 
transgenesis, in which a foreign gene (transgene) is introduced into an animal to give it a new 
property (hopefully to benefit mankind), and hopefully this new property is transmitted to its 
offspring.  The purpose of this chapter is to discuss the technology of transgenesis, describing 
what recombinant DNA is, how transgenic animals are made, and how they are screened.  This 
chapter will discuss the two main methods for creating transgenic animals: pronuclear 
microinjection and embryonic stem cell manipulation. We will also describe the two main ways 
potential transgenic positives are screened: polymerase chain reaction (PCR) and Southern blots.  
 
Manipulating DNA 
Transgenesis is a process stemming from a field of genetics called recombinant DNA 
(rDNA) technology.  Founded in the late 1950’s and early 1960’s, rDNA technology exploits the 
ability to isolate DNA, cut it into fragments, mix it, ligate it together, and replicate it.   
 
DNA 
An acronym for deoxyribonucleic acid, DNA is a long biopolymer consisting of repeated 
individual units known as nucleotides, arranged in two helical chains coiled together in a 
geometry called the ‘double helix’ (Watson and Crick, 1953). Four bases are fundamental to the 
structure of DNA, and include thymine, guanine, adenine, and cytosine. The sequence of these 
four bases forms the genetic code for all creatures on the planet. Through hydrogen bonding, 
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these four bases pair together according to the following pattern: adenine with thymine, and 
guanine with cytosine. The genome of a species contains all its hereditary information, which is 
encoded in the sequence of the base pairs.  When DNA replicates, each strand of DNA can act as 
a template for creating a new copy.  The capacity for DNA to replicate itself while maintaining 
its original sequence is the basis of amplifying it in vitro, which is used to create transgenes. 
 
Recombinant DNA 
Recombinant DNA (rDNA) is DNA modified to contain genetic information from two 
separate organisms. The first step of transgenesis is to identify the transgene of interest and 
amplify it.  For example, for transpharming animals (discussed in Chapter-2) the transgene might 
be a gene that encodes a human drug to save lives.  Or for Oncomouse, the transgene might be an 
oncogene that creates a disease model.  The transgene is either amplified from host DNA using 
PCR (discussed at the end of this chapter) or is separated from the rest of the host DNA by 
cutting with restriction enzymes.  Restriction enzymes are enzymes which cleave DNA at 
specific sequences in the DNA.  These enzymes are produced by bacteria to defend themselves 
against viruses by cutting the invading viral DNA (Pray, 2008). By using restriction enzymes to 
cut host DNA, specific segments of the DNA can be isolated.  If two different DNAs from two 
species are cut with the same restriction enzyme, the fragments have sticky ends that are 
compatible.  The sticky ends can be annealed together, and then sealed to produce rDNA.  DNA 
ligase is an enzyme used to seal pieces of DNA together.  DNA ligase is normally used by cells 
to repair DNA molecules using its ability to seal DNA together (Pray, 2008).  
Once the transgene has been amplified, it is usually cloned into a vector such as a 
plasmid DNA or virus to help make copies of the DNA (Transgenic Animals, 2003).  Plasmids 
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are small circular DNAs found in bacteria that, depending on the type of plasmid, replicate to 
high copy numbers separately than the host DNA.  Plasmids are the most frequently used cloning 
vector due to their ease of use.  Plasmid DNAs containing the ligated transgene are transformed 
into bacteria that help replicate it.  DNA viruses are also sometimes used as cloning vectors.  
After inserting the transgene into the virus, the virus is used to infect cells.  The cells are then 
grown to replicate the transgene.  Figure-1 summarizes the process of cloning a transgene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1:  Diagram of Transgene Cloning.  The schematic shows the process 
by which a transgene of interest is excised from the host DNA using restriction 
enzymes (panels 1 and 2), then are ligated into a plasmid or viral vector (panel-
3).  The vectors are then transformed (or infected) into host cells to replicate the 
transgene (panel-4).   (Biotechnology Information Series, 1995) 
 
In addition to cloning the transgene, a promoter is also usually inserted upstream from 
the transgene in the vector.  The promoter is a relatively short stretch of DNA that dictates which 
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tissue the transgene is expressed in, and at what levels (Harper, 1999). Promoters are used in 
various technology applications, such as in ‘transpharming’ where they force expression of the 
transgene in the animal’s milk to allow easy isolation of the pharmaceutical product.   
 
Constructing a Transgenic Animal 
As mentioned earlier in this chapter, there are two main methods for creating transgenic 
animals: microinjection into the pronucleus of a fertilized egg, and manipulation of embryonic 
stem (ES) cells. Other techniques can also be used, including somatic cell nuclear transfer 
(SCNT) and sperm-mediated DNA transgenesis, but these techniques are used less frequently.  
Each of these methods has advantages and disadvantages. 
 
Pronuclear Microinjection 
 Microinjection of the transgene into the pronucleus of a fertilized egg is the most reliable 
technique for transgenesis. In this method, the sperm and egg of an animal are united by in vitro 
fertilization (IVF).  Before the fertilized zygote begins dividing, it contains both the male and 
female pronuclei.  The male pronucleus is usually used for microinjection because it is slightly 
larger than the female pronucleus, and it is located on the periphery of the egg (Brinster et al., 
1985; Harper, 1999).  Microinjection is performed by a skilled lab technician.  A small suction 
pipette is used to hold the embryo in place, and a small diameter glass micropipette is used to 
inject nanoliters of DNA solution into the pronucleus (Figure-2). After microinjecting the 
transgene into the pronucleus, the embryo is allowed to grow and develop about 5 days to the 
blastocyst stage (about 100 cells), at which time it is implanted into the uterus of a surrogate 
mother that has been treated with hormones to induce an imitated physiological state of 
 9 
pregnancy to allow her to implant the blastocyst into the uterine wall (Gordon et al., 1980).  
Although microinjection is the most common technique for transferring the transgene into the 
pronucleus, other techniques can also be used including manipulated sperm, viruses, or 
chemicals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-2:  Diagram of DNA Microinjection into a Pronucleus.  The diagram 
shows a newly fertilized egg (diagram center) being held in place by a suction 
pipette (diagram right).  The slightly larger male pronucleus is then injected with 
nanoliters of transgene DNA solution using a very small bore glass injection 
needle (diagram right).  (Wiley Press Images, 2012) 
 
 
The pronuclear microinjection method has the advantage of being relatively reliable, and 
applicable to many different species.  In addition, because the animal is made transgenic at the 
single cell stage, all subsequent cells derived from the zygote will also be transgenic.  However 
this method has the disadvantage of randomly incorporating the transgene into the host genome.  
The random insertion can inactivate an important host gene, which is harmful to the host.  Or it 
can accidently activate an oncogene to induce tumor formation in the host.  Also, due to the 
uncontrolled, random insertion, some inserted transgenes will be active while others will be 
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inactive.  For this reason, it is necessary to screen potential pups to identify which ones actually 
contain and express the transgene.  
 
Embryonic Stem Cell Manipulation 
 The second most popular method for creating transgenic animals is the manipulation of 
embryonic stem (ES) cells (Bronson and Smithies, 1994).  ES cells are obtained from the inner 
cell mass of a blastocyst embryo.  At around 5 days (100 cells) the embryo consists of an outer 
layer of cells (the trophoblast) and an inner cell mass (ICM) containing ES cells.  ES cells have 
the unique property of being able to develop into any other type of cell or tissue in the adult 
organism, a property known as pluripotency. Since they are pluripotent, ES cells are often used 
for gene therapy to deliver a therapeutic gene to all adult tissues.  The ES cells are retrieved 
using a micropipette, and can either be stored frozen, or can be cultured to make an ES cell line.  
The DNA containing the transgene is inserted into the ES cells using electrical current 
(electroporation), chemicals, or viruses (Jaenisch and Mintz, 1974).  Microinjection is not 
usually used here due to the large number of ES cells that need to be treated.  The treated ES 
cells are then implanted into a blastocyst embryo, and as described before the embryo is 
implanted into a pseudopregnant mother.   
The two main advantages of using ES cells are 1) they allow a targeted insertion of the 
transgene to a known host site, and 2) the treated ES cells can be pre-screened for positives 
before implanting them into a blastocyst, increasing the efficiency of the process. The process 
whereby the transgene is targeted to a known location in the host genome is termed homologous 
recombination (Bronson and Smithies, 1994). In this process (Figure-3), segments of cloned 
host chromosomal DNA where the transgene is to be targeted (blue in the diagram) are inserted 
 11 
flanking the transgene (red) in the cloning vector.  These segments of DNA align and recombine 
with their counterparts in the host DNA, replacing the host DNA with the cloned DNA (diagram 
upper).  The figure also shows how cells containing the transgene can then be screened for 
antibiotic resistance (Neomycin-resistance, green gene) to improve efficiency.  A second 
screening gene, thymidine kinase (TK, purple) is lost in this process since it lies outside the host 
DNA.  During random DNA insertion (lower diagram) the TK gene remains with the transgene 
(Bishop and Smith, 1989).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3:  Diagram of Homologous Recombination Used to Target a Transgene to a Known 
Location in the Host Genome.   The upper half of the diagram shows a transgene (red with 
asterisk, diagram center) flanked by segments of host chromosomal DNA (blue).  During 
homologous recombination, the cloned host DNA pairs with the identical locations in the host 
genome, replacing the host DNA with cloned DNA (diagram upper).  In this process, note how the 
Neomycin-resistance gene (green) accompanies the transgene into the chromosome to allow 
screening of ES cells containing it.  And the gene encoding thymidine kinase (purple) is lost (it 
lies outside the chromosomal DNA).  The lower half of the diagram shows a random gene 
insertion, in which the TK gene remains present.  (RCN.com, 2012) 
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 While this method has the two advantages just discussed, its main disadvantage is it 
creates transgenic chimeras.  The blastocyst injected with the modified ES cells contains normal 
ES cells also present.  These non-transgenic normal cells give rise to tissues in the pups that are 
not transgenic.  So the pup is a mixture of tissues, some transgenic and some not.  Chimeric 
animals must be bred to other transgenics to eventually produce pure transgenic offspring 
(Brinster, 1974).  Figure-4 illustrates the two main methods of transgenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4:  Diagram of the Two Main Methods for Transgenesis. Method-1 
(diagram upper left) is ES cell manipulation, and Method -2 is pronuclear 
microinjection (diagram lower left). (RCN.com, 2012) 
 
SCNT 
Somatic cell nuclear transfer (SCNT) is another method of transgenesis.  In this 
technique, the nucleus from an animal’s somatic cell (usually a skin cell) is isolated and injected 
into an enucleated fertilized egg.  As the embryo develops, it contains the genetic material of the 
somatic cell; it is in every respect genetically identical to the organism from which the somatic 
nucleus was retrieved (Markoulaki et al., 2008). This method has been used for animal cloning, 
 13 
and was first applied to cloning Dolly the sheep, the first mammal to be cloned (Campbell et al., 
1996).  For the purpose of creating a transgenic animal, the somatic cell providing the donor 
nucleus would have to be modified to contain the transgene.  
 
Sperm-Mediated Transgenesis 
Sperm-mediated transgenesis is another method that can be used to create a transgenic 
animal.  In this case, are placed in culture with the DNA solution containing the desired 
transgene, which binds itself to the plasma membrane of the sperm. The sperm is then joined 
with an egg via in vitro fertilization. A disadvantage of this method is that it cannot be used for 
targeted gene insertion, because the sperm do not undergo homologous recombination (Bosch et 
al., 2004). In sperm-mediated transgenesis, random gene insertion occurs, so it has the same 
disadvantages as pronuclear microinjection. 
 
Screening Transgenic Positives 
 Since so many factors cannot be controlled during transgenesis, the process is very 
inefficient.  Only a tiny fraction of the manipulated embryos are born transgenic, so pups need to 
be screened to determine which ones incorporated the transgene into the genome.  The most 
popular techniques used for this screening are Southern blots and PCR. 
 
Southern Blots 
 Named after its inventor, Edward Southern, who invented the technique in 1975, the 
Southern blot technique enables one to separate and identify specific DNA fragments (such as 
those containing transgenes) (Southern, 1975). In this process (Figure-5), the host DNA is 
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isolated from a tissue such as a short tail section (or ear section or blood), and it is cut into 
fragments using restriction enzymes.  The cut DNA fragments are then separated by size using 
electrophoresis.  During this process, the DNA sample is layered onto a gel at one end, and an 
electric current is placed through the gel.  The positive anode is placed on the gel away from the 
DNA, and the negative cathode on the gel nearest the DNA.  The negatively charged DNA 
migrates toward the positive anode, with the smaller fragments migrating farthest (diagram upper 
left).  The DNA in the gel is then denatured to single strands using an alkaline NaOH solution 
(diagram upper right) and blotted to a membrane (diagram center) that allows the DNA to be 
hybridized to a labeled single-stranded probe complementary to the transgene (diagram lower).  
If the labeled probe hybridizes to a DNA fragment, the fragment is visible in X-ray film, and the 
animal is a transgenic positive. 
 
 
 
 
 
 
 
 
 
 
Figure-5:  Diagram of a Southern Blot.  This figure 
shows the process in which a DNA fragment containing a 
transgene can be identified by hybridization to a labeled 
probe that is complementary to the transgene.  The 
presence of a signal indicates the animal successfully 
incorporated the transgene.  (SIU.edu, 2012) 
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Polymerase Chain Reaction (PCR) 
 In comparison to the Southern blot technique, PCR is a faster and more sensitive method 
for screening transgenic animals (Mullis, 1990). In this technique (Figure-6), a very small 
sample of the animal’s DNA is obtained as described above.  Since PCR is a more sensitive 
procedure, so less DNA is necessary. The DNA is placed in a solution with a special DNA 
polymerase (Taq) that can catalyze the formation of new DNA at elevated temperatures.  The 
reaction tube also contains primers (sense and anti-sense to the transgene), and deoxy-
nucleotides as DNA precursors.  The reaction tube is heated to 94°C in a thermocycler (a 
programmable device to control temperature) and the DNA strands separate. The temperature is 
then lowered to approximately 55°C and the primers anneal upstream and downstream of the 
transgene if it is present in the DNA sample.  The temperature is then increased to 72°C the 
optimum temperature for Taq polymerase to synthesize more DNA using the primer sites to 
initiate the reaction.  This process is repeated several times until the transgene can be easily seen 
on a gel (Oste, 1988). If the animal is transgenic positive, in only a few hours, millions of copies 
of the transgene can be created and a band is seen on the gel.  If the animal is negative (did not 
integrate the transgene) no band is seen on the gel.  
 Although PCR is faster and more sensitive than Southern blots, it is prone to 
contamination.  It is so sensitive that a positive band can be amplified from extremely small 
amounts of lab DNA, for example contaminating the reaction from the pipettes used to add the 
solutions to the reaction tube.  Usually PCR is tried first, and if there is sufficient DNA and time 
allows, then Southern blots are performed for verification purposes. 
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Figure-6:  Diagram of PCR.  The figure shows the various steps of PCR, 
including DNA denaturation (upper right), primer annealing (right), and primer 
extension (lower right).  Note that the primers are designed to flank the 
transgene (yellow) on each side.  The amplification of a band denotes a 
transgenic positive that incorporated the transgene into its genome.  
(Berkeley.edu, 2012) 
 
 
Using the two screening methods outlined above, transgenic animals can be screened to 
detect the presence of the transgene in their genomes. If the transgenic animals test positive 
(usually only a small fraction of offspring), the positives are then bred with each other to 
establish a genetic line of transgenic animals, and to optimize expression of the transgene. In this 
way, transgenic animals, created for the purposes of scientific research, drug development, 
disease models, etc., can be created. 
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CHAPTER-2: TRANSGENIC APPLICATIONS 
Savan Ratanpara 
 
Now that we have discussed what transgenic animals are and how they are created, we 
turn our attention to which ones have been made.  The purpose of this chapter is to categorize the 
types of transgenic animals created to date, providing examples of specific animals within each 
category.  By describing which animals have been made, and why, we hope to lay the 
groundwork for later discussions in this project on whether such animals should be made.   
Transgenic animals have been used for various purposes, from creating disease models, 
to producing vaccines, to providing alternatives for human organ transplants. 
 
Transgenic Disease Models 
Disease models are animals created to mimic a specific human disease process (or a 
portion of it) for the purpose of studying disease formation or for screening potential therapies.   
Potential disease treatments must first be tested in animals before performing human clinical 
trials; but some human diseases are not found in animals.  So in this case, animals are engineered 
to receive a specific gene to enable the animal to mimic a human disease.  Transgenic models for 
human diseases such as AIDS, Alzheimer’s disease, or cancer have already proven very useful in 
scientific research. 
 
AIDs Mouse 
 AIDS is caused by the human immunodeficiency virus (HIV) that was first discovered in 
1983 (Barré-Sinoussi et al., 1983).  In nature, only humans and chimpanzees get infected by 
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HIV, as these organisms contain the correct combination of surface receptors (CD4 and CCR5) 
to allow HIV entrance into cells, and the correct host proteins to allow HIV replication.  But 
chimpanzees are not a good experimental model due to their high cost, so scientists engineered 
mice to mimic AIDS.  The first mice engineered to mimic AIDS were created in 1988 by two 
independent research teams.  One team was located in the Laboratory of Molecular 
Microbiology, at the National Institute of Allergy and Infectious Diseases, and injected cloned 
HIV pro-viral DNA into mouse pro-nuclei (Leonard et al., 1988).  None of the founder 
transgenic mice showed any symptoms of AIDs until mated with regular laboratory mice, then 
five of the F1 offspring of one founder showed disease symptoms such as pneumonia, enlarged 
spleens, and enlarged lymph glands. They all died in their adolescent age of 25 to 28 days.  Since 
the mice are not infected naturally, the model may not be useful for vaccine studies, but should 
prove useful for investigating the mechanism of symptom initiation. 
The second team to produce an HIV mouse in 1988 was located at Stanford University 
School of Medicine, who injected SCID mice with human lymph tissue followed by HIV 
injection (Namikawa et al., 1988).  SCID mice lack an immune system, so they do not reject 
transplanted human lymph tissue, which allows the tissue to become infected by the HIV 
challenge.   This model allows an analysis of HIV infection of human tissue in an in vivo 
environment.  The results of both of these HIV models are reviewed by Weiss (1988). 
 
Alzheimer’s Mouse 
 Alzheimer’s disease (AD) is a neurodegenerative disease caused by the buildup of a 
neurotoxin in specific areas of the brain related to learning and memory (Alzheimer’s 
Association, 2012).  The toxin is created by the improper processing of a cell surface protein 
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amyloid precursor protein (APP) to produce a smaller toxic protein amyloid-beta (Aβ).  AD 
affects humans 40 or above, and the incidence increases over time. Although five different drugs 
have been approved by the FDA for treating the symptoms, their effects are temporary, and there 
is no cure.   
Humans and orangutans get AD, but neither is a good experimental model, so scientists at 
WPI and the former Exemplar Corporation in Worcester helped create an AD mouse model 
(Games et al., 1995).  In this model, a form of human APP found in an Indiana family with an 
aggressive early-onset type of AD (Murrill et al., 1991) was inserted into the mouse genome by 
pronuclear injection. The gene was placed under the control of a PDGF promoter that expressed 
the transgene in the same areas of the brain affected in AD, the cortex and hippocampus.  By 6-8 
months of age, the mice showed signs of neuro-degeneration in the same areas of the brain as 
AD patients.  In 1999, this same strain of AD mice were used by Elan Pharmaceuticals to create 
a vaccine that removed the Aβ neurotoxin (Schenk et al., 1999), and the vaccinated mice showed 
behavioral improvements (Morley et al., 2002).  Figure-1 shows a later strain of AD mice 
created in 2012 at Case Western Reserve University. 
 
 
Figure-1: Photograph of Alzheimer's Mice in the Laboratory 
Created at Case Western Reserve University [FTC.gov, 2012] 
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 The creation of AD mice has allowed scientists to study the mechanism of senile plaque 
formation over time, and to screen potential AD treatments.  It also provides evidence that Aβ 
helps initiate AD and is not merely a side effect produced during the disease. The AD model 
should speed the development of drugs for treating AD in humans. 
 
Oncomouse 
 To further our understanding of cancer, in 1984 Harvard University in collaboration with 
DuPont designed a mouse that develops tumors by inserting the c-myc oncogene (that causes 
cancer) under the control of a mouse mammary tumor virus (MMTV) promoter to induce 
expression of the oncogene in mammary glands (Stewart et al., 1984). Prior to this model, 
scientists induced tumors in mice using irradiation, but the results were sporadic, so they needed 
a more reliable model.  Since the creation of the original oncomouse line, other lines have been 
created using other oncogenes and other promoters.  In 1988, the original c-myc oncomouse was 
patented in the U.S. making it the world’s first patented animal (Leder and Stewart, 1984).  
Oncomice have proved to be valuable for researching tumor formation, and for screening agents 
that block cancer.  The Oncomouse technology is widely used commercially (Bioethics and 
Patent Law, 2006). 
 
Transpharmers 
 Transpharming is the production of human pharmaceutical proteins in farm animals that 
have been genetically altered by the introduction of foreign genes into their chromosomes 
(Biotechnology Information…1995).  The added genes make it possible for the animal to create 
valuable proteins in milk, blood, urine, sperm, or eggs. These proteins have numerous uses, such 
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as the treatment of cystic fibrosis, anemia, hemophilia, osteoporosis, arthritis, malaria, and HIV. 
Transpharmers are also used to produce monoclonal antibodies as vaccines (Biotechnology 
Information…1995).  Milk is usually chosen as the fluid for production because the animals are 
not harmed when obtaining the drug, and the drug has no effects on the animal’s physiology.  
There is no harm to the animals since the mammary gland and milk are not part of the main life 
support systems of the animal. To get the new transgene expressed only in the milk, scientists 
join the transgene encoding the protein drug with a promoter for a milk protein (such as casein, 
whey acid protein, or beta-lactoglobulin) which are only active in the mammary gland. This will 
make the transgene expressed only where the milk is made. 
The first successful drug products of genetic engineering were proteins made in bacteria, 
like insulin in 1982 and growth hormone in 1987 (Pharmaceutical Product…. 2002).  E. coil can 
be used to inexpensively manufacture these drugs in bioreactors, but bacteria and other 
microorganisms cannot produce more complex human proteins that require post-translational 
processing such as carbohydrate addition or cutting to make an active product (Gillespie, 2010).  
Higher organisms, such as mammals, are needed because bacteria lack the enzymes needed to 
recognize the human protein sequences that need modification. Maintaining mammalian cell 
cultures is very expensive in comparison to the small amount of product that can be obtained 
from them.  
The world’s first animal transpharmer was a mouse engineered to produce the clot 
dissolver drug tissue plasminogen activator (tPA) in its milk (Gordon et al., 1987).  Other 
examples of drugs produced in milk by transpharming are antithrombin III (a blood thinner 
drug), erythropoietin (for treating anemia), blood clotting factors VIII and IX (for treating 
hemophilia), and alpha-1-antitryspin (for treating emphysema and cystic fibrosis) (Gillespie, 
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2010).  In addition, a goat has been engineered to express silk proteins in milk that can be spun 
into a fine thread with all the properties of spider-made silk. This could be used to make lighter, 
stronger bulletproof vests, thinner thread of surgery and stitches or indestructible clothes.   The 
world’s first FDA-approved transpharmed drug is ATryn®, anti-thrombin blood thinner (ATryn, 
2008) which has already been used to treat patients prior to surgeries. 
 
Xenotransplanters 
 Xenotransplantation is the use of animal organs for human transplants (Figure-2).  Every 
day in the U.S., approximately 18 people die from lack of available organs (Donate Life 
America, 2012). The problem with animal organs is they are viewed as foreign by a patient’s 
immune system, so scientists are engineering animals to make organs compatible with humans.  
A seventeen year old girl in Mexico was xenotransplanted with a pig organ and she was not 
required to take any other drugs for more than a year.  
 
Figure-2: An Art Depiction of Xenotransplantation.  
[Hanhvinh, 2010] 
 
 One form of xentranplantation has been practiced for years, the injection of animal 
tissues (not organs) into humans. For example, since 1988, Parkinson’s patients have been 
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injected with cadaver substantia nigra transplants (Madrazo et al., 1988), including animal tissue 
transplants.  And diabetic patients have been treated by injecting pancreatic β-cells into the 
patient’s pancreas which has restored normal serum glucose levels.  
However, scientists are more recently focused on using pig organs for transplant.  Pig 
organ donors are chosen more often than other animals because their organs approximate that of 
humans, and their physiology is somewhat similar.  But foreign proteins sugars on their surface 
(especially alpha-1,3-galactose) cause immune-rejection by the receiver.  So scientists have 
engineered transgenic pigs to lack the alpha-1,3-glactosyltransferase gene that helps place the 
sugar on the cell surface (Lai et al., 2002).  Their first experiment produced pigs lacking one of 
the two copies of this gene, so future experiments will be required to knock out both gene copies. 
 Xenotransplantation is a highly controversial topic worldwide. The main concern with 
xenotransplantation is that there could be endogenous viruses present in the pig donor and the 
viruses could cause an infection in the recipient.  So, scientists have proposed screening all 
potential pig donors for known viruses.  Retroviruses that may have integrated into the pig’s 
genome would require PCR to screen for them.  So the remaining risk would be an unknown 
virus that is not part of the screening process.  One way to help ensure the pig organs are 
harmless to humans is to screen the entire pig genome (DNA) for known viral sequences. But 
this would be a very time consuming task.  Although pig heart valves have been used for years 
for treating human valve problems, that tissue is not known to contain viruses. 
 Currently, a New Zealand research company Diatranz is the only laboratory in the world 
conducting a research into transplanting pig cells into humans (Catez, 2005). They provided pig 
cells for treating a 17 year old Mexican girl for diabetes. They are currently experimenting on 
injecting monkeys in Singapore with pig transplants. 
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Transgenic Food Sources 
 Transgenic food sources are animals that have been genetically modified to produce more 
food for human consumption. Although several species of plants have been created for potential 
human consumption, currently only two species of animals have been bred for this purpose: 
Superpig and Superfish. 
 
Superpig 
 Transgenic pigs have had a storied history in transgenesis.  The first transgenic pigs were 
created to contain human or bovine growth hormone genes under the control of strong 
metallothionein promoters to produce large pigs for consumption (Miller et al., 1989).  But these 
pigs developed very serious health problems, and had to be euthanized (Rollin, 1996), so 
scientists placed a moratorium on performing growth hormone experiments in farm mammals. 
However, a second type of transgenic pig has been created that might provide a healthy 
food choice for humans (Figure-3). These pigs are rich in Omega-3 fatty acids that are good for 
health (Marshall, 2006). Omega-3 fatty acids are found in fish oil and flax seeds at high 
concentration.  Regular meat contains Omega-6 fatty acids that are very harmful to humans; its 
high consumption can cause heart-disease, cancer, diabetes, and other diseases. The pigs also 
produce a lot more meat than a regular pig.  
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Figure-3: New Born Transgenic Pigs That Convert Unhealthy  
Omega-6 Fatty Acids to Healthy Omega-3 FAs.   [University of Missouri, 
2005] 
   
 The transgenic pigs contain a gene Fat-1 that allows the conversion of Omega-6 to 
Omega-3 fatty acids which are healthier for humans. The meat contains about five times the 
normal amount of Omega 3 FA’s; omega-3 FA’s make up made up an average of 8% of the 
total fat in the six transgenic piglets’ muscles, compared with 1 to 2% in normal piglets 
(Marshall, 2006). 
 
Superfish 
 Engineering superfish that contain growth hormone genes has had a nicer history than 
pigs engineered with the same genes.  In 1997, scientists created salmon containing an 
ocean pout growth hormone gene under the control of a promoter that allowed the hormone 
to be produced year round instead of seasonally (Devlin et al., 1997).  These salmon grew to 
a larger size than their non-transgenic littermates in less time, which is a strong advantage in 
the aquaculture industry.  Later in 2001, the same group inserted an antifreeze gene in the 
salmon to help prevent freezing in cold water (Devlin et al., 2001).  According to the 
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research group, the Salmon can grow up to 6 times larger than the regular salmon (Figure-
4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4: Comparison of Regular Salmon (left) to Genetically  
Engineered Salmon (right). (Consumers Want….2009] 
 
 These transgenic fish are near to receiving FDA approval for human consumption by 
Aquabounty Technologies, a biotech company located in Massachusetts (Aquabounty 
Technologies, 2012).  Some scientists are worried about the potential escape of transgenic fish 
into the wild, and their interbreeding with normal salmon. So, these concerns must be addressed 
before expanding this interesting technology.  Some of the superfish have been bred to be sterile, 
so even if they escape, they are incapable of producing offspring (Clarren, 2003). 
 
Scientific Models 
 Scientific models are created for the purpose of investigating the function of a newly 
discovered protein in vivo.  The gene encoding the new protein is either knocked out (to under 
express it), or it is over-expressed (to produce more of it than in normal animals), and then the 
effects on the animal are observed. 
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Smart Mouse 
 Neurobiologist Joe Tsien’s lab created a smart mouse by enhancing NMDA receptors in 
the brains of mice (Tang et al., 1999). The NMDA receptor in the brain functions in learning and 
memory.  The receptor is composed of different subunits, depending on the animal’s stage of 
development.  When the animal is young, the NR2B subunit predominates, so the authors’ 
hypothesized that by using transgenesis to over-express the NR2B subunit, this might enhance 
learning and memory in the mice.  Indeed, their data showed that adding a single NR2B gene to 
mice under a strong promoter boosted the animal’s ability to solve mazes, learn from novel 
objects, and test their environment. This research also provided proof to an old hypothesis 
proposed by Donald Hebb, termed Hebb’s rule, which states that strengthening a synapse by 
repeated firing improves its performance. 
 Previously, the Tsien lab showed that creating mice missing the NR2B gene hindered 
their cognitive performance; so this smart mouse experiment over-expressing NR2B was a 
logical extension of their earlier work.  Tsien’s first behavioral test for the mice over-expressing 
NR2B involved putting the mice in front of two play objects for several days.  Later, one object 
was replaced with a new one. The smart mice were able to recognize the new object as being 
novel, and spent more time exploring it than normal mice.  The second behavioral test involved 
testing emotional memory in the mice using cued fear; the mice were put into a chamber where 
they received mild foot pad shocks accompanied by a tone. About ten days later when they were 
put back in the chamber and given the tone, the smart mice had much more pronounced response 
than the control mice.  The third behavioral test involved fear-extinction testing.  In this test, the 
mice were originally taught to fear a tone as before, but then the shock no longer accompanied 
the tone.  The smart mice learned faster to ignore the tone.  Their fourth behavioral test involved 
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testing spatial learning. The mice were put into a pool of water with a flagged hidden platform in 
a specific location slightly underwater.  After the training phase, the flag was taken away and the 
smart mice spent more time in the correct location.  The smartmouse experiments show, in 
general, that over-expressing the NR2B subunit of the glutamate NMDA receptor improves 
cognitive performance on several types of behavioral tests.  This research could be helpful in the 
field of neurology and to help treat memory loss disorders (Harmon, (1999). 
 
Supermouse 
 Supermouse is a term for a mixed category of transgenic mice engineered to either be 
larger, stronger, or faster than normal mice.  Mice engineered to be larger were the world’s first  
expressing transgenic animals (Palmiter et al., 1982).  Earlier transgenic mice had been created, 
but they did not express their transgenes. This early strain of supermouse contained a growth 
hormone gene under the control of a strong always-on metallothionein promoter.   
A later type of supermouse was engineered to have greater physical stamina than normal 
mice (BBC, 2007).  These mice were engineered to contain 10-times more mitochondria than 
normal mice.  Mitochondria are organelles inside cells that provide energy.  The mice were 
shown to run five to six kilometers at 20 meters per minute for up to six hours without stopping.  
The mice eat twice as much as normal mice, but weigh half as much. Scientists say such work is 
helpful for understanding the physiology of stamina, and for potentially treating patients with 
muscle-wasting diseases (BBC, 2007). 
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Chapter-3: Transgenic Ethics 
Jeffrey Blanco 
 
In the first two chapters, the technology of transgenesis and the applications of that 
technology were detailed and explained.  In this chapter, the ethics of transgenesis, and whether 
it is appropriate to use this technology will be discussed, focusing specifically on the categories 
of transgenic animals discussed in Chapter-2: disease models, transpharmers, xenotransplanters, 
food sources, and scientific models. 
 
Introduction to Transgenic Ethics 
The ethics of transgenic animals is very complex, and it is exceedingly difficult to make a 
single policy in regards to what is appropriate, as each category of transgenic animal has its own 
problem for the animal and benefits to society. The problems to the animal can range from 
almost non-existent (if the health of the animal is unaffected by the transgene) to death (if the 
animal is sacrificed for food or organs, or suffers from cancer).  The benefits to society can range 
from providing known life-saving medicines, to having potential long-range unproven benefits 
of increasing our knowledge of a particular gene’s function.  Both the science and technology of 
transgenesis continue to improve, and with each improvement comes more ethical issues and 
concerns. While the first cloned animal, Dolly the sheep, was a significant step forward in the 
technology and science of genetic engineering (Campbell et al., 1996), it also resulted in the 
development of many more ethical concerns regarding the health of the animals and the morals 
of the technology. While the intent of most transgenic technology is for the benefit of mankind, 
such as with disease models which promise to yield treatments and cures, there is still a great 
deal of uncertainty surrounding the morality of the technology when it comes to the welfare of 
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the animals themselves. When considering animal welfare, it is sometimes difficult to accurately 
gage the level of animal suffering in transgenic applications; in some cases it is clear that the 
animal suffers, such as with cancer disease models, in other cases it is not so clear, such as with 
fairly benign things like transpharmers where the animal does not seem to suffer. The 
philosophical issues of whether animals actually possess a consciousness comparable to that of 
humans, and whether they truly perceive pain and suffering as humans do, are issues at the heart 
of transgenic ethics.  
 Ethical concerns of transgenic science are important for the practice to thrive and 
continue its growth, as it needs to have acceptance from the public for financial support. Ethical 
issues are important not just in transgenics, but in all areas of science and engineering since it 
provides the direct link between the science and the people who will be using and benefiting 
from the technology. The way science develops has historically been guided by the perceptions 
and opinions of the public, since it is public opinion which defines the subject matter of science 
and its methods (Rollin, 1996). This has been true in all areas of science and engineering, despite 
how disconnected many scientists and engineers may feel they are. In the end, scientific and 
engineering efforts are for the purpose of the advancement of humanity, and so ethical concerns 
deriving from societal views and opinions, guide the scientific and engineering efforts deemed 
important enough to follow. The methods of science are guided by ethics and morals as 
perceived by the public; an example is the simple fact that medical research is initially performed 
on mice and rats rather than humans.  Another example is that safety factors are strongly 
considered for different engineering projects depending upon the danger they pose to the public. 
Although science and engineering is governed by ethics and morality, few engineers and 
scientists actually consider the moral and ethical ramifications of their work prior to doing it, 
 36 
stemming from the point of view that science is not meant to make value judgments (Rollin, 
1996). As a result of this, many areas of science are in danger of being shunned by the general 
public, and transgenic animal research is especially in danger of this. It is important to consider 
the transgenic ethics since this it is necessary for the research to continue and receive acceptance 
from the public, for which it is devoted to improving. 
 
Disease Model Ethics 
 Disease models are transgenic animals created to exhibit a human disease process or 
specific symptoms of a human disease, for the purpose of disease studies and the development of 
treatments and cures. With this particular application of transgenic animals, the ethics involved 
are mainly concerning the welfare of the animal, since there is no direct involvement with other 
humans. For this reason, ethical arguments regarding the level of suffering the animal displays 
are the most relevant. However, there are still some concerns regarding other humans, in case the 
diseased transgenic animals accidentally escape their laboratory environment. An example of this 
hypothetical scenario has been discussed regarding the SCID-AIDS mouse.  As discussed in 
Chapter-2, SCID mice (lacking an immune system and allowing the engraftment of human 
tissues) are injected with human lymph tissue prior to being infected with HIV.  Although the 
animals themselves do not exhibit full AIDS symptoms, the human tissues present in them 
contain HIV, so some researchers have suggested that a bite from the mouse could infect 
humans, or the AIDS virus could become more virulent and infectious by interacting with other 
mouse viruses (if present), giving HIV new characteristics (Rollin, 1996). For this reason 
precautions are taken to prevent the mice from escaping, or from biting humans.  
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 Other than the possible scenario of diseased transgenic animals escaping their laboratory 
environments and infecting other humans, most ethical concerns are those regarding the welfare 
of the animals themselves. The AIDS  and the Oncomouse, are examples of transgenic animal 
disease models in which the animals truly suffer from their diseases, and there is little doubt as to 
whether the animals experience a high level of suffering. However, these animals are extremely 
valuable to medical research since they give deeper insight into the mechanisms involved in 
disease processes, helping tremendously with the development of cures and treatments from 
humans suffering from these diseases. With these animals, a value judgment is made wherein it 
is determined that the suffering of the animal is justified since it will reduce the suffering of 
another human. For religious institutions and practices, such as Christianity, Judaism, Islam, and 
Buddhism, the use of animals for disease models is usually justified since it will benefit humans 
in a positive way, and so it is considered permissible in most of these religions. In Buddhism, it 
is believed that as long as the suffering of the animal will benefit humanity in a positive way, 
leading to cures for diseases, then it is justified, otherwise if the suffering is for a less noble 
cause, the researchers will accrue bad karma in their lives (Buddhism and Animals, 2009). 
 Some other disease models exist in which the animals do not seem to suffer by any 
measurable degree. One example is the Alzheimer’s mouse model, developed at WPI and the 
former Exemplar Corporation (Games et al., 1995). With these mice, there does not seem to be 
any measurable amount of suffering, since Alzheimer’s disease is a disease which depletes the 
individual’s capacity for learning and memory, but does not cause any physical pain. Mice with 
AD exhibit behavioral characteristics which make them less able to adapt and learn to new 
environments, but the mice eat well, reproduce normally, and play normally. If the mice were 
released into a natural environment where they would be forced to fend for themselves, they 
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would be at a huge disadvantage and would most likely die, however being in the safety of their 
laboratory environment this is not a concern. For this reason, the AD mouse is one disease model 
in which the level of suffering is low enough that there appears to be little ethical concerns. 
These mice are also extremely valuable to Alzheimer’s disease research, and have already been 
used to help develop potential AD vaccines (Schenk et al., 1999), which more than justifies the 
behavioral disadvantages of the mice. 
 
Transpharmer Ethics 
 ‘Transpharming’ is a term used to describe the production of human proteins in farm 
animals for the purpose of creating life-saving pharmaceuticals. The human proteins are 
produced by transgenic animals like goats, sheep, and cows, and are created in the animal’s 
bodily fluids and secretions, such as in milk, blood, urine, sperm, or eggs. Most commonly, milk 
is the chosen medium from which to obtain the pharmaceutical proteins since it is easy to 
retrieve the protein, and the animals are not harmed when retrieving the product, and there is no 
effect on the animal itself, since the mammary gland and milk are not essential parts of the 
animal’s life support systems. For this reason, the animal does not appear to suffer by any 
measurable degree. In comparison to the other applications of transgenesis, transpharming has 
significantly less ethical concerns since the animals have a much lower risk for suffering and 
complications, so there is a somewhat less concern for the welfare of the animal. Transpharmers 
appear to be healthy and behave the same as any other animal that is not transgenic, only they 
produce valuable proteins which are a positive for humans and altogether irrelevant to the 
animal’s welfare. The only concern for this category is the fact that transgenesis is not a fully 
exact and accurate process, and there is always a risk that the transgene can be expressed 
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incorrectly in the wrong tissue, or be over-expressed causing complications (Gillespie, 2010). 
Despite this concern, which is always present in any application of transgenic animals, overall 
transpharmers present few major ethical problems. 
 
Xenotransplanter Ethics 
 Xenotransplanters are transgenic animals whose organs are used for human transplants. 
This application of transgenic animals is particularly promising for the thousands of individuals 
needing organ transplants. The issue of availability of organs for transplantation is notoriously 
severe, especially since every day in the U.S. approximately 18 people die due to the lack of 
available organs (Donate Life America, 2011). Animal organs are foreign to the human body, so 
they are typically rejected by the patient’s immune system, and for this reason transgenic animals 
are used to produce organs from animals that are compatible with the human body. Most often, 
pigs are used as xenotransplanters, since the organs and anatomy of the pig is similar to humans. 
The main ethical concern regarding xenotransplantation is the potential risk of the transmission 
of diseases from the animal organs to humans, especially if the patients are on immune-
suppressive drugs.  In a book written by Bryan and Clare, the authors follow the lives of patients 
who received pig brain cell implants, and discuss the dangers involved when humans are 
exposed to diseases during operations (Bryan and Clare, 2001). There have also been concerns 
raised over knockout piglets regarding whether they harbor viruses capable of infecting humans 
(Butler, 2002). In order to prevent the communication of diseases during xenotransplantation, 
many have proposed screening all potential pig donors for known viruses and agents. The 
potential for infection from pig viruses and foreign diseases is the main ethical concern 
surrounding xenotransplanters.  
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 Besides the danger xenotransplanters pose to humans regarding infectious diseases, there 
is also the ethical concern regarding the animals themselves. In xenotransplanters, the animals 
are sacrificed for their organs; a value judgment is made in that this sacrifice is justified since the 
life of a human is saved. This is somewhat similar to the value judgment made sacrificing 
millions of farm animals daily for human consumption to save lives. Similar to the other 
categories of transgenic animals, since they benefit humans, and since humans are considered by 
some to be of higher value than animals, the suffering and death of the animal is considered 
permissible. For most religious groups and institutions, since human lives are saved, the death of 
the xenotransplanter animal can be justified. All that can be done to address this particular 
concern for the welfare of the animal is to ensure that the animal is sacrificed as humanely as 
possible. 
 
Transgenic Food Source Ethics 
 Transgenic animals have also been produced to provide more food for human 
consumption. Thus far, only two species of animals have been engineered for this purpose, pigs 
and fish, and neither has yet gained approval by the FDA for human consumption. Historically, 
the transgenic superpigs (containing growth hormone genes) have suffered more than transgenic 
superfish. Transgenic food sources are ripe with ethical concerns, since this particular application 
seems to present a high cost in terms of animal suffering with the benefit, of a higher yield for 
the food industry, being one for which it is hard to justify the cost.  
 For most of human history, there has been a certain degree of “genetic engineering” 
through selective breeding of farm animals via the natural processes of biology.  And traditional 
farming depended on adhering to the natural needs of animals. But the advent of modern genetic 
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engineering has bypassed the natural constraints of farming, by producing animals that have been 
enhanced artificially for short term gains, even though there may be cause for concern in the long 
term (Almond, 2000). The food industry is a huge industry driven by mostly economic concerns, 
such that ethical issues involving the welfare of animals are often ignored for economic benefit. 
One famous example of issues involving the welfare of the animals is the case of the “Beltsville 
pigs.” These pigs had human growth hormone genes to accelerate the rate of growth, however 
they suffered from severe health problems, including lameness, ulcers, cardiac problems, and 
reproductive complications (Christiansen and Sadoe, 2000).  Despite the health issues with the 
pigs, if the preserved pain and suffering of the animals did not impair production efficiency then 
likely the issues would have been ignored by most. However, the production priority over animal 
welfare is not the fault of transgenic animal technology, but is rather endemic to livestock 
industry (Christiansen and Sadoe, 2000).  Seventeen of the nineteen ‘Superpigs,’ produced by the 
Beltsville Superpig experiment died within a year due to health problems, ranging from 
pneumonia and peptic ulcers (“Uniqueness of Transgenic Animals,” 2002).  
 In comparison to transgenic pigs, transgenic fish have fared well in terms of health 
problems. Transgenic salmon, termed “Superfish,” developed either no diseases or less severe 
symptoms in comparison to the Superpigs. However, some Superfish did develop certain growth 
abnormalities in the head and jaw, causing complications that made it difficult for the fish to eat 
(Eenennaam, 2006). However, these initial problems were solved and overcome by further 
research. As mentioned in Chapter-2, transgenic fish produced by Aquabounty Technologies in 
Massachusetts may soon become approved by the FDA for human consumption (Aquabounty 
Technologies, 2012). Though there are concerns that the transgenic fish may accidentally escape 
their cages and mate with wild salmon (Kohler et al., 1992), these concerns have been addressed 
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by breeding the Aquabounty fish to be sterile. Overall, it would seem that the issues surrounding 
transgenic fish have been somewhat solved, and perhaps with further research, the health issues 
with transgenic pigs will also be solved. 
 
Transgenic Scientific Model Ethics 
 Scientific models are transgenic animals created for the purpose of investigating the 
function of newly discovered proteins in vivo. Similar to disease models, scientific models are 
transgenic animals created to observe the effects of new proteins in animals. With scientific 
models, usually the animal does not suffer, especially in comparison to disease models in which 
certain diseases are purposefully induced in the animals, but some gene knockouts are later 
shown to inhibit early development, etc.  Examples of scientific models as discussed in Chapter-
2 include the smart mouse created in Joe Tsien’s lab and the supermouse. Most scientific models 
are transgenic mice created for the purpose of investigating the function of newly discovered 
genes encoding proteins. Over-expressing or under-expressing one gene often presents no strong 
overall effect on the animal, but is some instances it can result in death.  With the smart mouse, 
behavioral experiments were performed in which the mice experienced a mild shock to their foot 
pads accompanied by a tone to investigate associative learning, to determine how an over-
expressed gene affected associative memory. Most would conclude that the mild foot shock does 
not constitute a severe level of suffering, since the mouse only experiences it for a very short 
period of time and no physical long term effects are observed. For the most part, scientific 
models do not pose strong ethical concerns, except to specific extreme animal rights groups who 
are against the use of animals for any scientific purpose. These animals provide valuable insight 
into the function of newly discovered genes and proteins, benefitting scientific knowledge. As 
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with disease models, the knowledge obtained from scientific models benefits humanity, and 
contrary to the disease models, most of these animals do not experience any severe pain.  
 
Chapter-3 Conclusions 
 The ethical issues surrounding transgenic animals, as with any new, emerging field in 
science, will always remain in the public consciousness as long as the usual cultural biases 
against genetic engineering of any kind continue. It is common with any new field in science that 
extreme views will dominate the public opinion, especially since the public is often ill-informed 
of the science itself (Rollin, 1996). Alarmist media coverage is often to blame for the extreme 
views upheld by the public in regards to genetic engineering, and very often the average person 
is not willing to take the time to learn the truth of the science itself.  For this reason, it is 
important that scientists and engineers seriously approach ethical issues surrounding their work, 
since science is not entirely value free.  
The ethics of transgenic animals is especially difficult, since each application of the 
technology holds very different circumstances for both the animals and the humans involved. 
Since each application as discussed in this chapter is so different, it is not possible to follow a 
single rule policy to determine whether the use of transgenic animals is acceptable. It is of the 
opinion of the author that most of the transgenic animals applications discussed here are 
acceptable and do not pose significant insurmountable ethical concerns, since most are for the 
benefit of humanity and have the potential to help those in need.  It is only the applications of 
transgenic animals as food sources that I believe there are significant ethical concerns, since the 
animals do suffer a great deal (die) for a cause that is not quite as noble (growing faster) as with 
disease models or transpharmers. Transgenic mammals used for food sources suffer from many 
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health problems, and yet there is little regard for those animals since the food industry is largely 
concerned with profit. The ethical issues surrounding transgenic animals used for food sources 
are also issues endemic to the entire food industry, where animals are sacrificed daily for human 
food to benefit man.  Regardless of the use of transgenesis in the food industry, it is common to 
be a less than desirable level of concern for animal welfare for animals raised by industrial 
farms. However, transgenic animals do provide a means to advance the food industry such that 
conventional small farmers can no longer compete with large industry. The use of transgenesis is 
a side-effect of the larger issues with the food industry, since these concerns exist even without 
transgenesis.  
Overall, using the ethical argument of always trying to maximize animal welfare, and 
maximizing the benefit to humanity, the author believes that most transgenic animal applications 
are acceptable and should continue. With further research, the ethical issues that remain can be 
solved, which is exemplified by the progress with transgenic fish. In order to continue research 
in transgenic animals, however, it is essential that the scientists and engineers educate 
themselves and discuss the concerns expressed by the public to eventually receive the acceptance 
they need.  The more informed the public and scientists are of transgenic animals and the issues 
surrounding them, the better the technology and science will get, and the greater the benefit to 
humanity. 
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Chapter-4:  Transgenic Legalities 
Savan Ratanpara 
 
 
 Controversial technologies need laws regulating their use.  After discussing the ethics of 
transgenic animals, in this chapter we discuss the laws associated with transgenesis, including 
the general pros and cons of animal patenting, the patenting of the first transgenic organism (a 
microbe engineered to eat oil slicks), and the patenting of the first transgenic animal (the disease 
model Oncomouse).  
 
Should Transgenic Animals be Patented? 
 Even though genetically altered animals have provided disease models for studying 
disease causes and therapies, transpharmers that produce life-saving drugs in their milk, 
xenotransplanters that produce organs for transplant into humans, and food sources that mature 
faster on less food, the use of animals for the benefit of humans has disappointed some Animal’s 
Rights Activists.  Patenting animals has both pros and cons.   
With respect to the positive aspects of animal patenting, some scientists argue that 
allowing animal patents encourages further medical research by rewarding companies that create 
the animal in the first place.  These profits can be re-invested back into the same company to 
fund research groups that develop more models for studying human diseases or producing more 
drugs (Ching, 2003).  As new genetic diseases are discovered, creating new transgenic animals 
that mimic those diseases aids our understanding of the new disease, and speeds the 
identification of potential treatments.  perform more medical research.  Allowing animal patents 
would encourage scientists to conduct more experiments with the technology, and reward the 
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most successful groups for the duration of the patent.  By growing the industry, more high-tech 
jobs would be created. 
However, other individuals argue that animal patenting should not be allowed.  Some 
scientists argue that patents actually deter scientific innovation; the licensing fees charged by the 
patent holder for any scientist working with the animal might discourage some of the smaller 
academic labs with more limited resources than larger profit-making companies.  Indeed, this 
was originally the case with Oncomouse where the initial licensing fees were approximately 
$5,000, and these were lowered over the years to zero dollars for non-profit universities (Kevles, 
2002).  Time and energy are taken away from scientific innovation, and instead are spent on 
negotiating the payment of licensing fees.  Research shows that 20% of scientists delay 
disseminating their research findings to the public to file their patent (Ching, 2003), which 
hinders other scientists from using their results to make other advancements.  Some people see a 
forthcoming danger that accompanies transgenic technology by allowing companies to patent 
specific genetic manipulations that raises many ethical, legal, and policy questions about whether 
genetic sequences themselves can be patented.  Some of the major concerns with patenting 
animals are: a) potentially negative environmental consequences, b) the potential abuse of 
animals, and c) the potential misuse of human genetic engineering (Fielder, 1997). 
 
Environmental Risks 
 Some individuals argue that transgenic animals are likely to escape in the wild, and the 
impact on the environment would be significant. Many examples already exist of escaped 
animals, or animals brought to a country to help “balance” another species, such as the gypsy 
moth, the kudzu vine, and rabbits in Australia.  Gypsy moths are severe tree defoliators (Figure-
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1) and one of the most destructive forest pests in the United States (Estes, 2009).  They were 
brought here intentionally to aid the silk industry by increasing the disease resistance of silk-
producing caterpillars, but the gypsy moth escaped from its silk producing cages, and became 
established in throughout the northeastern states south to Virginia and west to the Great Lakes 
Region.  Although female gypsy moths do not fly, they lay their eggs near feeding areas (picnic 
tables, firewood, grills, cars), and this is how they spread (Estes, 2009).   The defoliated trees 
makes them vulnerable to diseases or other pests (Minnesota….2012). 
 
 
 
 
 
 
 
 
Figure-1: Photograph of Defoliation Caused by the Gypsy Moth. 
This species of moth was brought to the U.S. to facilitate the silk 
industry, but escaped its cages to become one of the worst forest pests in 
the entire United States.  (Estes, 2009) 
 
 In 1995, an Australian scientist wanted to perform tests on a deadly rabbit disease called 
Rabbit Hemorrhagic Disease (RHD). The experiment was conducted on Wardang Island,  in the 
Southland of Australia three miles from the mainland. Unfortunately, a diseased rabbit escaped 
its containment and made it to the mainland, causing an outbreak that killed millions of wild and 
pet rabbits (Wegner, 2003).  The field tests were allowed, even though scientists did not 
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understand how RHD spread or how it killed rabbits.  RHD is now endemic to Australia and 
most of Europe, and has since broken out in the USA (Wegner, 2003).  
It is difficult to predict the consequences of transgenic animal escapes. Likely, it would 
depend on which type of animal escaped.  For example, Aquabounty’s superfish have been 
engineered to be sterile, so if they escape and interbreed with normal salmon, no offspring would 
be created (Aquabounty, 2012). 
 
Abuse of Animals 
 Animal Rights Activists are afraid of the potential for animal abuse with transgenic 
technology.  For example, with disease models, scientists purposely engineer the animals to 
mimic one aspect of a human disease.  Frequently the animals do not develop the full symptoms 
of the disease, but they can suffer for example in the case of oncomouse.  And now that the 
world’s first transgenic monkey ANDi has been been created (Chan et al., 2001), perhaps the 
next animal created will be Oncochimp, an animal much closer to humans in the evolutionary 
scale (Fielder, 1997). 
 Another potential source of animal abuse could be creating transgenic animals for 
entertainment.  Animals are widely used for public entertainment in circuses and carnivals. In 
traditional circuses, exhibitors had to rely on naturally occurring genetic mistakes to show off 
their two headed cows, but genetic engineering opens up the possibility of designing misshapen 
animals. There will, no doubt be an audience for circuses of strange and pitiful transgenic 
animals, as well as entrepreneurs willing to exhibit them and scientists to produce them. The 
question is whether a humane society should permit it (Fielder, 1997).  Based on the types of 
transgenic animals created to date, each of which provides a direct medical or food benefit to 
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society, likely this type of entertainment experiment would never be approved by today’s 
Institutional Animal Care and Use Committees (IACUC) that require extensive documentation 
about why the experiment must be done.  So we must be constantly on vigil to prevent such 
experiments from being performed. 
 As one example, scientists placed a voluntary moratorium on growth hormone 
experiments in mammals based on the terrible side effects observed with one of the original 
superpig experiments (Miller et al., 1989).  The pigs exhibited crossed eyes, disabling arthritis, 
and premature death (Dresser, 1988). Other transgenic pigs had uncoordinated gait, lethargy, 
lameness, degenerative joint disease, and thickened skin (Pursel et al., 1989). 
 
Misuse of Human Genetic Engineering 
 Some scientists fear that genetic technology might not only be used for animals, but also 
for humans.  Some fear that genetic technology might be used not just to cure some genetic 
disease, but to produce a specific cosmetic improvement, like someone who is taller or has a 
particular color of eyes.  Giving the excuse of “improving” one’s offspring would be thrown 
around when trying to perform genetic engineering on humans. Should companies, who hold 
patents on specific genetic disease sequences, be the only scientists allowed to treat those 
diseases?  For cosmetics, it would be easy to imagine a lowering of diversity and a potential 
homogenization of society (Fielder, 1997).  Fortunately for society, it is currently illegal to 
perform germ-line altering gene therapy on human beings, or to perform reproductive cloning.  
Currently in humans, the only type of genetic alterations allowed is to treat somatic cells for 
known fatal genetic diseases. 
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World’s First Patented Organism 
  The world’s first patent awarded for a living organism was for a Pseudomonas bacterium 
engineered to eat oil slicks.  In 1972, Ananda Mohan Chakrabarty, a microbiologist working for 
General Electric in the U.S. applied for a patent for his invention of a genetically engineered 
bacterium (Figure-2) created by adding two different plasmids to the wild-type organism, each 
of which provided a separate pathway for breaking down the components of crude oil.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-2:  Photograph of the World’s first Patented Microbe.  Shown 
in the photograph is the Pseudomonas bacterium engineered in 1972 by 
Ananda Chakrabarty to contain extra genes that enables it to use oil as a 
food source.  (Castor, 2009) 
 
The case known as Diamond v. Chakrabarty was opposed by Sidney Diamond, the 
Commissioner of Patents and Trademark who stated that the U.S. has never allowed living 
organisms to be patented.  The initial application was turned down by the patent examiner, and 
by the Board of Patent Appeals and Interferences, who stated that according to the law, living 
organisms are non-patentable.   
In 1980, Chakrabarty appealed the case to the Supreme Court where Diamond v. 
Chakrabarty became a landmark case in patent law. The case lasted in the Supreme Court for 
two months, and the judges ruled in favor of Chakrabarty with 5-4 vote, approving the patent 
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under section 35 U.S.C 101 Inventions Patentable that states, “Whoever invents or discovers any 
new and useful process, machine, manufacture, or composition of matter, or any new and useful 
improvement thereof, may obtain a patent therefore, subject to the conditions and requirements 
of this title” (Bitlaw, 2000).  The court stated that the bacterium was Chakrabarty’s own 
manufacture, and it would be useful during oil spills. The patent novelty requirement was also 
met as there are no naturally occurring bacteria with the same capabilities, and the non-obvious 
requirement was clear-cut. 
 
History of the First Animal Patent 
Following the award of a patent for the first living microbe, the first animal patent was 
applied for in 1983-84 (Leder and Stewart, 1984) by Dr. Philip Leder and Dr. Timothy Stewart 
who worked at Harvard Medical School.  The patent application was for Oncomouse, also 
known as The Harvard Mouse, which was genetically altered to contain the c-Myc oncogene 
under the control of a mouse mammary tumor virus promoter to produce strong expression in 
mammary tissue.  The American chemical company DuPont provided six million dollars 
financial support for the research, and the patent was also in their name.  In April 1988, the first 
animal patent in the world, entitled “Transgenic nonhuman mammals”, was awarded to DuPont.  
However, DuPont’s aggressive approach to license the mouse and require licensing fees 
up to $5,000 invited controversies from academic institutions and US National Institute of Health 
(NIH) about concerns that compliance with the license terms would seriously affect basic 
research and hinder the search for new cancer therapies, as only the wealthy pharmaceutical 
companies could afford the high licensing fees.  In 1999, after four years of negotiation, DuPont 
and NIH signed a Memorandum of Understanding (MOU) that allowed NIH to conduct basic 
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research on Oncomouse provided that the research would not benefit any commercial interests. 
This did not stop DuPont from collecting royalties from the academic institutions like the 
University of California who stated that they are entitled to research on Oncomouse just as much 
as NIH.  Citing the provisions of the MOU, the University of California countered DuPont’s 
demands with an offer to take a license on Oncomouse using the same no-cost terms and 
conditions provided to NIH.  The University of California’s research mission was consistent with 
the terms and conditions of the 1999 MOU.   DuPont normally charged fees to institutions that 
received NIH funding.  These institutions are so-called ‘recipient institutions’ descried in the 
MOU that could be allowed to conduct research on Oncomouse without any fees.  But DuPont 
argued that these institutions also received funds from their sponsoring companies, and the 
research could ultimately be used for commercial purposes which would be considered as “direct 
benefit” to the competing company.  
 The University of California disagreed, stating that even though the research is funded by 
a sponsoring company, it serves as a “direct benefit” to the University Mission of Research. The 
university has an official policy of insisting that research be conducted in an open academic 
environment, and in a manner consistent with the freedom to publish (University of California… 
2004).  The University of California pointed out MOU’s section that says, “DuPont agrees that it 
shall make Harvard Patent Rights available for use by nonprofit recipient institutions under 
separate written agreements in accordance with the terms and conditions outlined above.” The 
matter was taken to NIH and they concluded that the university’s interpretation of the MOU is 
correct, and that they should be allowed to conduct research on Oncomouse without paying fees 
(Blaug et al., 2004). 
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 In the meantime, Dr. Philip Leder and Dr. Timothy Stewart also received two more 
patents, one in 1992 and the other in 1999. U.S. patent 5,087,571 issued in 1992, covered the 
method for preparing a cell culture from a non-human mammal, and U.S. patent 5,925,803 
issued in 1999, covered the testing method using transgenic mice expressing an oncogene. 
Following the approval of the U.S. Oncomouse patent in April 1988, similar patents were also 
approved in Australia, Japan, and some European countries.  Since the Oncomouse case, over 
600 patent applications for transgenic animals have been submitted in the U.S. 
 
Canada’s Oncomouse Case 
 Although the patent for Oncomouse was awarded in the U.S., it was denied in Canada.  
The Supreme Court of Canada turned down the case of patenting higher life forms on the 5
th
 of 
December, 2002, and Canada remains the only industrialized country that does not allow patents 
on higher life forms.  Canada allows patents on single-cell organisms like bacteria, but does not 
allow patents on more complex life forms. Initially, Canada’s Commissioner of Patents approved 
the patent. But under opposition, an appeal was made, and it was turned down by the Trial 
Division of the Federal Court. Then the Federal Court of Appeal overturned the decision by a 
ruling of 2-1. Finally the case was brought to the Canadian Supreme Court that blocked the case 
with 5-4 vote, stating that a living mouse cannot be patented (Ching, 2003). 
 The Canadian Supreme Court argued that a mouse is not an “invention.” An invention in 
the Canadian Patent Act is defined as “any new and useful art, process, machine, manufacture or 
composition of matter, or any new and useful improvement in any art, process, machine, 
manufacture or composition of matter.”  Similar words like “manufacture” and “composition of 
matter” are also described in the US Patent Law of Section 101- Inventions Patentable, which 
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was used to approve the Oncomouse patent case. But the Canadian government argued that 
“manufacture” denotes a non-living entity, and that “composition of matter” is a phrase that must 
be considered in the context of the other words. Justice Michael Bastarache of the Canadian 
Supreme Court said, “Just as ‘machine’ and ‘manufacture’ do not imply a living creature, the 
words ‘composition of matter’ are best read as not including higher life forms” (Ching, 2003).  
The Canadian court argued that an animal’s capacity to display emotions and to behave 
unpredictably separates them from lower life forms, and shows they are more than a composition 
of matter.  Justice Binnie expressed his concerns that allowing patents to mice would open up 
doors to patenting humans. And ownership of humans for commercial purpose is ungrateful to 
the nature.  Thus, the Canadian Supreme Court decided that genetic modifications of mice should 
not be patented in Canada, unless the issue is resolved in the Parliament following a debate.  
 The decision was saddening for many Canadian pharmaceutical companies who were 
patiently waiting for the Supreme Court ruling on the case. Over 1,500 applications for patents 
on plants and animals were awaiting the Canadian decision.  One scientist stated that, “Canadian 
scientists are at risk of being left behind their colleagues around the world” (Ching, 2003). 
 
Chapter-4 Conclusion 
 Patents for transgenic microbes and animals has had a storied past with a variety of 
highly debated court cases.  The U.S. led the way by patenting the worlds’ first microbe in 
Diamond v Chakrabarty in 1980, and by patenting Oncomouse in 1988.  Proponents of animal 
patents argue that scientists devote their time, money and hard work to secure a patent over their 
discovery or invention, which then brings financial benefits to that company and stimulates 
medical research. Patenting new scientific discoveries brings accolades to their achievements, 
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but it should not hinder further research by requiring excessively high licensing fees, as 
originally occurred with Oncomouse.  Transgenic animals have many benefits to society, but we 
should be well aware of any risks associated with animal escape, or hindering medical progress 
by attempting to patent genetic sequences themselves.  Transgenic animal patents have also been 
awarded in other countries such as Japan and several European countries, but Canada on the 
other hand took a more literal interpretation of the phrase “composition of matter”, and 
concluded it could not apply to animals, so they currently disallow any animal patents. 
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PROJECT CONCLUSIONS 
 
 
 
 In this project, the technology of transgenic animals was discussed, focusing on the 
science of transgenesis, the applications for which they are used, how they are classified, their 
ethical concerns, and the legalities of patenting animals. A transgenic animal is an animal that 
has been genetically engineered to contain within its genome a foreign gene from another 
animal. The inserted gene, called a transgene, is expressed in the animal in such a way that 
provides new characteristics to the animal that it would not otherwise exhibit. The transgene can 
give the animal the ability to produce pharmaceutical proteins in its milk, or display the 
symptoms of a human disease for the purpose of medical research. In Chapter-1 the science of 
transgenesis, the process by which transgenic animals are made, was discussed in detail, 
outlining how transgenic animals are made and the methods for screening transgenic animals.  
Regardless of which technology is used to create them, pronuclear microinjection or embryonic 
stem cells, the process is not efficient.  
 There are five main categories of transgenic animals demonstrating the different 
applications of this technology, including disease models, transpharmers, xenotransplanters, food 
sources, and scientific models. Each of these categories was discussed in detail in Chapter-2, 
providing example animals for each category. The ethical concerns regarding transgenesis were 
considered in Chapter-3, including animal welfare and environmental concerns. There are 
several ethical concerns that must be considered for this technology, and each type of animal 
must be carefully considered separately, as each brings a unique benefit to society or a unique 
mode of potential suffering.  The ethics of transgenic animals is very complex, and includes 
questions of whether animals possess a consciousness comparable to humans, and how to 
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accurately gage an animal’s welfare given our inability to communicate or understand animals. 
For the most part, the ethics of transgenic animals follow the general argument that one must 
maximize the level of welfare for animals as well as the benefit to humanity. In certain cases, the   
suffering of the animal is justified given that it is for a noble cause, such as with disease models, 
though in other cases the benefit seems harder to justify the cost, such as with the Superpigs who 
suffered painful side effects while providing little societal benefit.  The authors of this project 
agree that as far as ethical concerns are considered, most of the applications of transgenic 
animals should continue and do not pose insurmountable concerns, with the exception of “Super 
mammals” such as Superpigs, for which the welfare cost of the animal is much too high given 
the presumed benefit.  
 There are a great number of legal concerns for transgenic animals as well, specifically 
whether transgenic animals should be patented. The main issue in patenting transgenic animals is 
the fact that the invention being patented is a living thing, and given the legal language definition 
of a patent, anything that is naturally occurring does not quite constitute a new composition of 
matter or an invention. Canada has used the argument that an invention must be a new 
“composition of matter,” and that transgenic animals do not qualify.  Thus, Oncomouse, the 
world’s first patented animal, was allowed a patent in the U.S., Europe, and Japan, but not in 
Canada.  Patents provide potential benefits which include protecting a company’s profits 
allowing the expansion of medical research. Although there is an issue when the licensing fees 
are so high that smaller labs are discouraged from performing research. It is of the opinion of the 
authors of this paper that transgenic animals should be allowed to be patented, provided that it 
encourages and does not hinder research. Transgenic animals have much potential to benefit 
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humanity, and for this reason the issues brought up in this paper should be seriously considered 
by both scientists and engineers as well as the general public. 
 
